ERBB2 and neoplasm: It is encouraging to conclude that these researchers reported that the combination of the resultant trio adenovirus with HER2-redirected CAR-Ts resulted in more reliable tumor rejection and survival through the engagement of non-specific immune cells, while compared with the respective monotherapies (144).